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A fluoro-analogue of the potent narcotic antagonist, naltrexone, was synthesized and shown to bind with 
high affinity to opiate receptors in vitro. 3-[‘*F]acetylcyclofoxy was prepared via a one-step triflate displace- 
ment reaction with the positron emitting r*F ion from tetraethylammonium [r*F]fluoride. 3-[r*F]acetylcyclo- 
foxy accumulation in opiate receptor rich brain regions of both rat and baboon is shown to be completely 
displaced by the active enantiomer of naloxone ((-)-naloxone) while the identical dose of the pharmacologi- 
cally inert (+)-naloxone has no detectable ffect. Moreover, both rat and baboon brain showed the well 
documented, typical opiate receptor distribution so that basal ganglia and thalamus are clearly visible in 
the living baboon brain up to 95 min after intravenous injection of 3-[‘*F]acetylcyclofoxy. We expect that 
3-[r*F]acetylcyclofoxy will be a useful probe for visualizing opiate receptors in living humans. 
Opiate receptor PET 3-[i8F]Acetylcyclofoxy Stereospecificity Naloxone 
1. INTRODUCTION 
Pharmacological theory dictates that most drugs 
bind initially to discrete tissue constituents termed 
‘receptors’ to exert effects in the living animal. In 
vitro binding of tritiated opiates to rat brain mem- 
branes was the basis for the initial demonstration 
of opiate receptors in brain [ 1,2]. There is a precise 
correlation between the in vivo effect of opiate 
derivatives and the affinity of this binding in vitro 
over a broad range of pharmacologic potencies 
[3,4]. A striking demonstration of receptor- 
relevant biochemical interactions is the high degree 
of stereoselectivity [5] shown by enantiomeric pairs 
of opiate agonists such as morphine [6] and the an- 
tagonist naloxone [7]. These pairs differ by 
lOO&lOOOO-fold in binding affinity for the active 
and inactive enantiomers. Recently, a number of 
unnatural opiate enantiomers have been synthe- 
sized in quantity for the first time [g-lo]. These in- 
clude (+)-naloxone which we use here to 
demonstrate the stereospecific binding of 
3-[18F]acetylcyclofoxy (3) to opiate receptors in the 
brain of a living baboon. 
o To whom correspondence should be addressed 
A great deal is currently known about the 
distribution of opiate receptors in mammalian 
brain. Studies of dissected, homogenized brain 
regions [ 11,121, as well as autoradiographic [ 13,141 
patterns of opiate receptor distribution on thin sec- 
tions of rat brain consistently show high levels of 
radiolabeled opiate-binding sites in the caudate 
nucleus/basal ganglia, thalamus, and prefron- 
tal/frontal cortex with undetectable binding in the 
cerebellum. Moreover, dissection [ 151 or visualiza- 
tion [ 161 of intravenously injected radiolabeled 
opiates also demonstrates a similar pattern of 
anatomical localization. We now show that 
3-[“Flacetylcyclofoxy binds in vivo in rat and ba- 
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boon in the expected opiate receptor patterns in a 
stereospecific manner. 
Opiates containing positron emitting ra- 
dionuclides have been proposed as suitable probes 
for detecting opiate r ceptors in living humans 
[17-191. However, 3-[“F]acetylcyclofoxy is the 
first positron emitting opiate for which the active 
and inactive forms of naloxone were used to une- 
quivocally demonstrate stereospe~ific displace- 
ment from opiate receptor-rich regions. 
3-li8F]Acetylcyclofoxy thus fulfills the dual 
criteria of stereospecific displacement and concor- 
dance with the previously demonstrated neuro- 
anatomical pattern of opiate receptor distribution 
in rat and primate brain. 
2. MATERIALS AND METHODS 
2.1. Chemistry 
3-Acetyl-6-deoxy-6-~-[~*FJfluoronaltrexone (3- 
[“F]a~etylcyclofoxy (3)) was synthesized (fig. 1) 
from the known 3-acetyl-6_cu-naltrexol (1) via the 
triflate 2. The latter was prepared by treatment of 
(1) with trifluoromethanesulfonic anhydride in 
chloroform containing excess pyridine as described 
in [20]. i8F was produced from 6Li$Z03 using the 
high flux reactor (1.1 x lOi n/cm’ per s) at the 
National Bureau of Standards. The reaction of 
triflate 2 with Et4N”F in anhydrous acetonitrile 
containing Et4NOH at 80°C for 0.25 h provided 
3-[‘sF]acetyIcyclofoxy (3). The product was purified 
on reversed-phase HPLC eluted with 55% MeOH, 
45% Hz0 with 5 mM octanesulfoni~ acid at pH 3 
to give a 30% radiochemical yield uncorrected for 
decay. The lower limit of the effective specific ac- 
tivity at the time of injection was approximately 
20 Ci/mmol assuming that all chemical impurities 
have the same extinction coefficient and the same 
opiate receptor affinity constant (see [ZO]). By 
Scatchard analysis of 3-[‘8F]acetylcyclofoxy (3) 
and ( -)-[3H]naloxone binding to rat brain mem- 
branes the specific activity was estimated to be ap- 
prox. 50 Ci/mmol. 
2.2. Eioc~emistry 
Stereospecific opiate receptor binding to rat 
brain membrane in vitro was measured with non- 
radioactive (-I-)- or (-)-naloxone (low6 M) and 
( -)-[3H]naIoxone (New England Nuclear) on 
f3HJFoxy (13H]-5) [ZI] as described. Accumulation 
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of injected 3-[**F]acetylcyclofoxy in vivo was 
measured by scraping approximately equivalent 
areas of anatomically distinct horizontal sections 
(24 microns) (fig.2a) into detergent fluor, 
sonicating and counting at 90% efficiency by li- 
quid scintillation spectrophotometry. The image of 
3-[‘*F]acetylcyclofoxy accumulation in cryostat- 
cut 120 micron horizontal brain sections was ob- 
tained from a rat injected in vivo with 30,&i 
3-[1sF]acetylcyclofoxy and sacrificed 30 min later 
by decapitation; the section was juxtaposed over- 
night against Kodak S20 film and developed in the 
standard way the following morning (fig.2b). 
2.3. Imaging procedure 
The role of opiate receptor binding in the 
anatomic localization of 3-[“Flacetylcyclofoxy 
was studied using (+)-naloxone (6) (inactive) and 
(-)-naloxone (7) (active) (fig.3). A 16 kg male ba- 
boon was studied on 2 successive days: August 30 
and 31, 1984. The animal was sedated with 
1.5 mg/kg ketamine and 0.4 mg/kg Ropum and 
intubated. He was placed supine on a rigid table 
for the PET tomography, allowed to breath 40% 
oxygen and maintained under anesthesia by a con- 
tinuous i.v. infusion of 4.8-6 mg/kg per h sodium 
pentothal. On each imaging day, after the animal’s 
vital signs had stabilized, a rapid bolus injection of 
340 pCi 3-[“Flacetylcyclofoxy (3) was made. The 
anesthetized baboon was positioned identically on 
both days in the ring of a high-resolution positron 
emission tomograph, the Neuro PET [22]. 
The experimental sequence was identical on both 
days, with the exception that just prior to image 
17, (- )-naloxone was injected on August 30, and 
saline injected August 31. The following ex- 
perimental sequence was employed: image l-5, 
1 min per image; image 5-10, 5 min per image; 
image 1 I-19, 10 min per image. Just prior to im- 
age 11, saline was given; prior to image 14, (+)- 
naloxone was given and prior to image 17, saline 
(August 3 1) or (-)-naloxone (August 30) was 
given. At each image collection period, 5 
tomographic slices were obtained parallel to the 
canthomeatal line with the position of the slices at 
37 mm below, to 20 mm above the c-m line. Peak 
count rates obtained were about 10000 cps for all 
slices. The attenuation coefficient was calculated 
by considering each slice to be an ellipse defined by 
a region of interest drawn just external to the scalp 
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1: 3-ACeTYL-6cr- 
NALTREXOL 
5. 6-DEWY-&2,-FIJORO- 
OXYM0RPH0NE (FOXY) 
2. 3-ACETYLds- 
NALTREXOL TRWLATE 
3, R = CH3C0, 3-ACZTYL-&DEOXY- 
f$-FLUORONALTREXONE (3-ACETYL- 
CYCL0FmY) 
4. R = H, 6-DEOXY-6glW.Z0RO- 
~ALT~~O~ KYCLOmiY~ 
6. (+)-WLOXONE 7: (-)-NALoxoNE 
Fig. 1. Synthesis of 3-[‘“F]acetylcyclofoxy (3); structures of Foxy (5) and ( + )- and ( - )-naioxone (6 and 7, respectively). 
seen on early view. Image reconstruction was per- 
formed using a filtered back-projection technique. 
Attenuation corrected, reconstructed images where 
photographed from the CRT screen onto 
transparency film using a l%.mn Photomat, at each 
imaging interval. 
3. RESULTS 
Fig.1 shows the route of chemical synthesis for 
[‘~~acetylcyclofoxy (3), as well as structures for 
the enantiomers (+ )- and ( - )-naloxone (6 and 7, 
respectively), and foxy (5), the agonist analogue of 
cyclofoxy which, as expected from previous 
reports 1231, fails to accumulate in vivo. Synthesis 
of the highly reactive triflate precursor of 
3-acety~cyclofoxy provided a rapid, one-step 
radiochemical labeling procedure. We chose in- 
troduction of the fluoro substitution at the 6 posi- 
tion of the morphinan ring system since this posi- 
tion is easily manipulated in 1 and such modifica- 
tions generally give active compounds [24]. 
Cyclofoxy [2OJ as expected, at 2 nM retained the 
high affinity of its prototype naltrexone (1 nM) in 
in vitro binding experiments. 3-[“F]Acetylcyclo- 
foxy binds in vitro stereospecifically to opiate 
receptor membrane preparations. Horizontal brain 
sections of rats injected with 3-[“Flacetylcyclo- 
Foxy showed an accumulation pattern in vivo 
(table 1, fig.2b) quite similar to that of in vitro 
stereospecific [3H]naloxone binding (fig.2a). 
Moreover, ( - )-nalaxone (1 mg/kg) completely 
blocked regional brain accumulation. The same 
Table 1 
Comparison of 3-[~sF]ace~yIcy~~ofoxy (226&i/220 g 
rat) accumulation in several regions of brains of rats co- 
injected with (- ) or (-I-) non-radioactive naloxone 
(1 mg/kg) and killed after 30 min 
Regionb ( - )-Naloxone ( + )-Naloxone 
(cpm/72 pm slice) 
Cerebellum 64+ 9 47-t- 8 
Collicuh 58 f 10 134 -r- 12a 
Thalamus 784 I1 260 f 22” 
Caudate 80& 9 214 +- lga 
a Values represent X f SE determined in quintuphcate 
for each of 2 rats 
b As diagrammed in fig.2A 
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Fig.2. (a) An autoradiograph of a horizontal section (24 microns) of rat brain with in vitro labeling of opiate receptors 
(in white) with [‘Hlnaloxone illustrates the plane of dissection used to obtain table 1 data [13]. (b) An image-enhanced 
autoradiograph of a horizontal section (120pm) of brain from a rat injected with 3-[‘*F]acetylcyclofoxy (see section 
2). The very short (110 min) half-life of 18F necessitated a thick brain section to obtain this low-resolution image. 
dose of ( + )-naloxone had no effect. We constantly 
monitored the relative specific activity (N = 5) by 
measuring the caudate: cerebellum ratio of accu- 
mulation (5-8 : 1) after 3-[‘*F]acetylcyclofoxy 
injection. 
( + ~-~a~oxone 
(60-70 mid 
( + ~-~a~oxone 
min) 
An anesthetized baboon injected with 
3-[‘*F]acetylcyciofoxy showed the striking and 
dramatic pattern expected for opiate receptor 
distribution (fig.3). Moreover, a low dose of (-)- 
naloxone (0.13 mg/kg) completely abolished this 
( - )-~a~oxone 
Saline 
W-95 mid 
Fig.3. Sequential positron emission tomography in a living baboon after intravenous injection of 3-[‘“F]acetylcyclofoxy 
and subsequent injections of (+)- or (-)-naloxone (0.13 mg/kg). Sections at eye level show receptor unrelated non- 
displaceable ‘*F accumulation by melanocytes in the retina [31]. 
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pattern, while the identical dose of (+)-naloxone 
injected before a previous lo-min time segment did 
not alter the pattern. The following day, once 
again it was shown that (+)-naloxone failed to 
reduce the striking pattern of opiate receptor 
distribution in baboon brain, since 3-[“Flacetyl- 
cyclofoxy is still clearly visible in the basal ganglia 
and thalamus at 95 min post-injection (fig.3). 
4. DISCUSSION 
Generally, while psychoactive drugs always bind 
in vivo to their brain receptors, their accumulation 
in receptor-rich areas can seldom be measured over 
the ‘noise’ of unbound drug. Studies of bound vs 
unbound radiolabeled opiates accumulated in 
regions of rat brain at various times after in- 
travenous injection have revealed that the percen- 
tage of receptor-mediated accumulation increases 
with time [15]. We show that 3-[‘*F]acetylcyclo- 
foxy is a useful probe for visualizing stereospecific 
opiate receptor binding in vivo; both the rat slice 
and baboon brain images clearly display the ex- 
pected opiate receptor pattern. Initially, the 
3-[“F]acetylcyclofoxy is distributed to all regions 
by blood flow. We observed rapid efflux of radio- 
activity from many opiate receptor-poor regions 
such as cerebellum and occipital cortex. In con- 
trast, 3-[“Flacetylcyclofoxy was retained in the 
basal ganglia and thalamus. 
Since probes with highest receptor affinity are 
most useful for visualizing receptors, opiate an- 
tagonists accumulate much more readily than their 
agonist analogs [23] in the sodium-rich in vivo en- 
vironment. Thus, it is clear that 3-[“F]acetylcyclo- 
foxy is an antagonist. [3H]Foxy, its agonist analog, 
shares a high in vitro (sodium-free) affinity in the 
l-2 nM range [21] but fails to accumulate in vivo 
(caudate : cerebellum = 1). Previously documented 
in vivo binding has been reported for antagonists 
only, including [3H]naloxone [15] and [3H]dipre- 
norphine [ 161. 
Acetylation in the 3 position, e.g., heroin, in- 
sures an efficient initial delivery to brain (about 
5% vs morphine’s less than 0.1%). Interestingly, 
by analogy with the rapid deacetylation of heroin 
in vivo [25], phenolic cyclofoxy is probably the ac- 
tive species in brain. Foxy is an acronym for 5, a 
fluoro derivative of oxymorphone; we refer to the 
N-cyclopropylmethyl analog 4 as cyclofoxy. 
A recent paper [26] suggests that region-specific 
opiate receptor binding in vivo is susceptible to 
blockade by the endogenous opiate peptides (i.e., 
endorphins/dynorphins/enkephalins) released by 
environmental stimuli. This raises the exciting 
possibility that the functional aspects of opiatergic 
neurocircuitry in individuals might be assessed if
3-[“F]acetylcyclofoxy, as expected, is suitable for 
human use. Fortunately, 3-[18F]acetylcyclofoxy 
appears to label the rather interesting p (an- 
tagonist) conformation of the type I opiate recep- 
tor complex. These opiate receptors show an ex- 
ponential increase along monkey cortex from the 
visual cortex (back of brain) to the frontal cortex, 
a cortical distribution pattern corresponding to the 
increasing complexity of sensory information pro- 
cessing occurring along this gradient [27]. Here 
(image not shown), the frontal cortex of the living 
baboon was apparently labelled with 3-[“Flacetyl- 
cyclofoxy; it is exciting to contemplate studies of 
the larger human cortex where the neuronal 
macromolecules we call opiate receptors, which 
have appeared relatively recently in evolution [28], 
are densest in those expanded regions [29,30] serv- 
ing ‘higher’ functions. 
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